---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-000247"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:14:48.209511+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma FY2023 net loss $32.5M; Mino-Lok Phase 3 enrollment done, topline Q2 2024

## Summary
- Net loss $32.5M ($0.22/share) for FY ended Sep 30, 2023; cash $26.5M, runway through Aug 2024.
- Mino-Lok Phase 3 completed (241 patients, 109 events); topline results expected Q2 2024.
- LYMPHIR BLA resubmission on track for early 2024 after July 2023 CRL; PDUFA later in 2024.
- Halo-Lido Phase 2b completed; end-of-Phase 2 meeting with FDA planned early 2024.
- Oncology subsidiary to merge with TenX Keane Acquisition (TENKU) to form publicly listed Citius Oncology.

## SEC filing metadata
- accession: 0001213900-24-000247
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/0001213900-24-000247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/ea190916-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-000247
- JSON: https://secwatch.observer/filing/0001213900-24-000247.json
- Plain text: https://secwatch.observer/filing/0001213900-24-000247.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported fiscal full year ended September 30, 2023 results: net income Net loss was $32.5 million, or ($0.22) per share, EPS ($0.22) per share.
  - Period: fiscal full year ended September 30, 2023
  - Net income: Net loss was $32.5 million, or ($0.22) per share
  - EPS: ($0.22) per share
  - Result: reported results
  source text: Net loss was $32.5 million, or ($0.22) per share for the full year ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/0001213900-24-000247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.